AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
Status:
Withdrawn
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out what effects, administering infusions of AUY922 with
hormonal therapy (letrozole) and oral targeted drug (lapatinib) will have on the patients
with advanced breast cancer known as ER+ HER2 +.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Texas Tech University Health Sciences Center, El Paso